Angion (ANGN) Kidney Drug Misses Third Study Goal in 2021

Angion (ANGN) Kidney Drug Misses Third Study Goal in 2021

Angion ANGN and partner Vifor Pharma announced that the phase II GUARD study evaluating lead candidate, ANG-3777, in patients undergoing cardiac surgery involving cardiopulmonary bypass with risks of developing acute kidney injury (CSA-AKI) did not achieve the primary endpoint.

Angion (ANGN) Kidney Drug Misses Third Study Goal in 2021 – Zacks

The GUARD study was designed to determine the feasibility of advancing ANG-3777 into a phase III study in patients having CSA-AKI, for which there are currently no approved therapies.

The GUARD study failed to achieve its primary endpoint of percentage increase in serum creatinine based on the area under the curve, with no significant difference in the short-term endpoint between ANG-3777 and placebo.

Nonetheless, the study did indicate a potential benefit in patients receiving ANG-3777 over those receiving placebo, based on the secondary endpoint of MAKE90. MAKE90 is a composite endpoint combining death, initiation of renal replacement therapy, or a greater than 25%…

Continue reading